A Study of RO4989991 in Patients With Allergic Rhinitis

Completed · Phase 1 · Has a placebo group

Conditions studied: Asthma

In brief

This multi-center, randomized, observer-blinded, placebo-controlled study will evaluate the safety and tolerability of subcutaneous doses of RO4989991 in patients with allergic rhinitis who are otherwise healthy. The anticipated time on study treatment is 2 weeks.

Key facts

Study ID

NCT01152619

Run by

Hoffmann-La Roche

People needed

24

Starts

2010-07-01

Expected to finish

2011-02-01

Last updated by the study team

2016-11-02

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients, 18-65 years of age, inclusively
• A history of allergic rhinitis diagnosed by a physician, but otherwise healthy
• A positive skin prick test to at least one standardized allergen at screening
• A body mass index (BMI) between 18 and 32 kg/m2, inclusively

You may not qualify if…

• History or presence of any respiratory disease or condition other than allergic rhinitis
• Use of prescription medication or herbal remedies within 14 days of dosing the study drug
• Use of over-the-counter (OTC) medications within 7 days of dosing the study drug
• Acute infection (including viral infections) 6 weeks (8 weeks for respiratory infections) preceding dosing or any ongoing chronic infection
• Positive test for human immunodeficiency virus (HIV) or hepatitis B or C

Where it is running

• Study site — South Miami, Florida, United States
• Study site — Normal, Illinois, United States
• Study site — Raleigh, North Carolina, United States
• Study site — Spartanburg, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.